Cognate Bioservices takes in Series B, also buys Cobra Biologics

Cognate Bioservices, a contract development and manufacturing organization specializing in cell and cell-mediated gene therapy products, has closed its Series B funding round.

Cognate Bioservices, a contract development and manufacturing organization specializing in cell and cell-mediated gene therapy products, has closed its Series B funding round. No financial terms were disclosed. The investors include EW Healthcare Partners. In addition to the funding, Cognate acquired Cobra Biologics, a provider of development and manufacturing services for the plasmid DNA and viral vector.

Source: Press Release